OBJECTIVE: Several smaller single-center studies have reported a prognostic role for Ki-67 labeling index in prostate cancer. Our aim was to test whether Ki-67 is an independent prognostic marker of biochemical recurrence (BCR) in a large international cohort of patients treated with radical prostatectomy (RP). METHODS: Ki-67 immunohistochemical staining on prostatectomy specimens from 3,123 patients who underwent RP for prostate cancer was retrospectively performed. Univariable and multivariable Cox regression models were used to assess the association of Ki-67 status with BCR. RESULTS: Ki-67 positive status was observed in 762 (24.4 %) patients and was associated with lymph node involvement (LNI) (p = 0.039). Six hundred and twenty-one (19.9 %) patients experienced BCR. The estimated 3-year biochemical-free survivals were 85 % for patients with negative Ki-67 status and 82.1 % for patients with positive Ki-67 status (log-rank test, p = 0.014). In multivariable analysis that adjusted for the effects of age, preoperative PSA, RP Gleason sum, seminal vesicle invasion, extracapsular extension, positive surgical margins, lymphovascular invasion, and LNI, Ki-67 was significantly associated with BCR (HR = 1.19; p = 0.019). Subgroup analysis revealed that Ki-67 is associated with BCR in patients without LNI (p = 0.004), those with RP Gleason sum 7 (p = 0.015), and those with negative surgical margins (p = 0.047). CONCLUSION: We confirmed Ki-67 as an independent predictor of BCR after RP. Ki-67 could be particularly informative in patients with favorable pathologic characteristics to help in the clinical decision-making regarding adjuvant therapy and optimized follow-up scheduling.
OBJECTIVE: Several smaller single-center studies have reported a prognostic role for Ki-67 labeling index in prostate cancer. Our aim was to test whether Ki-67 is an independent prognostic marker of biochemical recurrence (BCR) in a large international cohort of patients treated with radical prostatectomy (RP). METHODS: Ki-67 immunohistochemical staining on prostatectomy specimens from 3,123 patients who underwent RP for prostate cancer was retrospectively performed. Univariable and multivariable Cox regression models were used to assess the association of Ki-67 status with BCR. RESULTS: Ki-67 positive status was observed in 762 (24.4 %) patients and was associated with lymph node involvement (LNI) (p = 0.039). Six hundred and twenty-one (19.9 %) patients experienced BCR. The estimated 3-year biochemical-free survivals were 85 % for patients with negative Ki-67 status and 82.1 % for patients with positive Ki-67 status (log-rank test, p = 0.014). In multivariable analysis that adjusted for the effects of age, preoperative PSA, RP Gleason sum, seminal vesicle invasion, extracapsular extension, positive surgical margins, lymphovascular invasion, and LNI, Ki-67 was significantly associated with BCR (HR = 1.19; p = 0.019). Subgroup analysis revealed that Ki-67 is associated with BCR in patients without LNI (p = 0.004), those with RP Gleason sum 7 (p = 0.015), and those with negative surgical margins (p = 0.047). CONCLUSION: We confirmed Ki-67 as an independent predictor of BCR after RP. Ki-67 could be particularly informative in patients with favorable pathologic characteristics to help in the clinical decision-making regarding adjuvant therapy and optimized follow-up scheduling.
Authors: Sven Gunia; Knut Albrecht; Stefan Koch; Thomas Herrmann; Thorsten Ecke; Volker Loy; Jörg Linke; Michael Siegsmund; Matthias May Journal: World J Urol Date: 2008-04-05 Impact factor: 4.226
Authors: Thomas J Sebo; John C Cheville; Darren L Riehle; Christine M Lohse; V Shane Pankratz; Robert P Myers; Michael L Blute; Horst Zincke Journal: Am J Surg Pathol Date: 2002-04 Impact factor: 6.394
Authors: L Cheng; T M Pisansky; T J Sebo; B C Leibovich; D M Ramnani; A L Weaver; B G Scherer; M L Blute; H Zincke; D G Bostwick Journal: Clin Cancer Res Date: 1999-10 Impact factor: 12.531
Authors: Anthony V D'Amico; Richard Whittington; S Bruce Malkowicz; Kerri Cote; Marian Loffredo; Delray Schultz; Ming-Hui Chen; John E Tomaszewski; Andrew A Renshaw; Alan Wein; Jerome P Richie Journal: Cancer Date: 2002-07-15 Impact factor: 6.860
Authors: Joseph J Fantony; Lauren E Howard; Ilona Csizmadi; Andrew J Armstrong; Amy L Lark; Colette Galet; William J Aronson; Stephen J Freedland Journal: Biomark Med Date: 2018-06-15 Impact factor: 2.851
Authors: Priscilla Léon; Geraldine Cancel-Tassin; Sara Drouin; Marie Audouin; Justine Varinot; Eva Comperat; Xavier Cathelineau; François Rozet; Christophe Vaessens; Steven Stone; Julia Reid; Zaina Sangale; Patrick Korman; Morgan Rouprêt; Gaelle Fromond-Hankard; Olivier Cussenot Journal: World J Urol Date: 2018-04-20 Impact factor: 4.226
Authors: Giancarlo Marra; Marco Oderda; Giorgio Calleris; Alessandro Marquis; Federica Peretti; Andrea Zitella; Marco Moschini; Rafael Sanchez-Salas; Robert Jeffrey Karnes; Burkhard Kneitz; Martin Spahn; Donatella Pacchioni; Paolo Gontero Journal: Transl Androl Urol Date: 2022-09